Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2023-10-11
2028-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
NCT03047135
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
NCT01972217
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)
NCT03434158
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
NCT03570476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician
* Who have been informed and are not opposed to this data collection
Exclusion Criteria
* Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Amiens, , France
Research Site
Angers, , France
Research Site
Antony, , France
Research Site
Argenteuil, , France
Research Site
Avignon, , France
Research Site
Avignon, , France
Research Site
Besançon, , France
Research Site
Bordeaux, , France
Research Site
Bordeaux, , France
Research Site
Challes-les-Eaux, , France
Research Site
Chambray-lès-Tours, , France
Research Site
Chambray-lès-Tours, , France
Research Site
Champigny-sur-Marne, , France
Research Site
Clermont-Ferrand, , France
Research Site
Clermont-Ferrand, , France
Research Site
Compiègne, , France
Research Site
Créteil, , France
Research Site
Créteil, , France
Research Site
Epagny METZ Tessy, , France
Research Site
Epagny METZ Tessy, , France
Research Site
Ermont, , France
Research Site
FORT de France, , France
Research Site
Fréjus, , France
Research Site
Fréjus, , France
Research Site
Grenoble, , France
Research Site
Le Chesnay, , France
Research Site
Le Coudray, , France
Research Site
Le Coudray, , France
Research Site
Le Mans, , France
Research Site
Levallois-Perret, , France
Research Site
Lyon, , France
Research Site
Lyon, , France
Research Site
Mantes-la-Jolie, , France
Research Site
Mantes-la-Jolie, , France
Research Site
Marseille, , France
Research Site
Morlaix, , France
Research Site
Nancy, , France
Research Site
Nancy, , France
Research Site
Nantes, , France
Research Site
Nice, , France
Research Site
ORL ANS, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Pointe à Pitre, , France
Research Site
Poitiers, , France
Research Site
Pontoise, , France
Research Site
Quint-Fonsegrives, , France
Research Site
Rouen, , France
Research Site
Rouen, , France
Research Site
Saint Denis- LA Reunion, , France
Research Site
Saint-Doulchard, , France
Research Site
Saint-Etienne, , France
Research Site
Saint-Etienne, , France
Research Site
Saint-Grégoire, , France
Research Site
Saint-Grégoire, , France
Research Site
Saint-Mandé, , France
Research Site
Saint-Nazaire, , France
Research Site
Saint-Nazaire, , France
Research Site
Strasbourg, , France
Research Site
Suresnes, , France
Research Site
Tours, , France
Research Site
Tours, , France
Research Site
Vannes, , France
Research Site
Vantoux, , France
Research Site
Vantoux, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0817R00049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.